Paricalcitol

帕立骨化醇

Report date: 2022/01/14 13:23:58
NME

Base Information

Drug NameParicalcitol
Drug Alias Nameparicalcitolum帕利骨化醇ParacalcinZemplar胜普乐 +[7] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionVitamin D analoguesVitamin D receptor agonists
TargetsVitamin D receptor
Therapy Area/IndicationsRejection of renal transplantationInflammationHyperparathyroidism, Secondary +[21] 
Global Approved IndicationsHyperparathyroidism, SecondaryRenal Insufficiency, Chronic
Approved Indications in ChinaHyperparathyroidism, Secondary
Original Approved Country/TerritoryUnited States
Original Approved Date1998/04/17
Country/TerritoryCzechiaUnited StatesTaiwan +[20] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesAbbvie Inc
China Registration ClassN/A

Develop Information

Active CompaniesQingdao Guoxin Pharmaceutical Co LtdAbbvie SrlAbbvie Inc +[4] 
Inactive CompaniesAbbott LaboratoriesChinese University Of Hong Kong (Cuhk)Wake Forest University Health Sciences +[12] 
Active IndicationsHyperparathyroidism, SecondaryHyperparathyroidismRenal Insufficiency, Chronic +[4] 
Inactive IndicationsRejection of renal transplantationInflammationVitamin D Deficiency +[17] 

Other Information

ATC CodeH05BX02
Related LinksWikipediaDrugBankKEGG